Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Lengout

Lengout
In stock
0.5mg
from A$61.22
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$73.47A$61.22
A$2.04 per tablet

In brief

  • In our pharmacy you can buy lengout without a prescription, with delivery across Australia and discreet packaging available.
  • Lengout (colchicine) is used for acute gout flares, gout prophylaxis, Familial Mediterranean Fever (FMF) and as low‑dose therapy in some cardiovascular risk settings; it works by binding to tubulin and inhibiting microtubule polymerisation, reducing neutrophil migration and the inflammatory response.
  • The usual dose is: acute gout — 1.2 mg at onset then 0.6 mg 1 hour later (do not exceed 1.8 mg in 1 hour); prophylaxis — 0.6 mg once or twice daily; FMF — typically 1.2–2.4 mg/day in divided doses (children ≥4 years start 0.6–1.2 mg/day); cardiovascular use — 0.5 mg once daily.
  • Form of administration: oral tablets (0.6 mg), capsules (0.6 mg) or oral solution (0.6 mg/5 mL).
  • Onset time: symptom relief commonly begins within 12–24 hours, with some patients noticing improvement within a few hours of the first dose.
  • Duration of action: anti‑inflammatory effects typically persist for about 24–48 hours; prophylactic dosing is taken chronically at the lowest effective dose.
  • Do not consume alcohol — alcohol can increase gastrointestinal side effects, worsen liver disease and may trigger gout flares, so avoid or minimise alcohol while taking lengout.
  • The most common side effect is diarrhoea; other frequent effects include nausea, vomiting and abdominal pain, and less commonly fatigue, myalgia, reversible hair loss and blood dyscrasias.
  • Would you like to try lengout without a prescription?

Critical Warnings & Restrictions

Basic Lengout Information

  • INN (International Nonproprietary Name): Colchicine.
  • Brand Names Available In Australia: not specified.
  • ATC Code: M04AC01.
  • Forms & Dosages:
    Form Strength(s) Example Brands
    Tablet 0.6 mg Colcrys, Lodoco
    Capsule 0.6 mg Mitigare
    Oral Solution 0.6 mg/5 mL Gloperba
  • Manufacturers In Australia: not specified.
  • Registration Status In Australia: Approved in Australia (check the TGA ARTG for current product registrations).
  • OTC / Rx Classification: Prescription only / Rx in regulated markets.

High‑Risk Groups

Who should get an immediate pharmacy or medical review before colchicine is prescribed?

  • Older or frail patients, who are at increased risk of toxicity and adverse events.
  • Pregnant or breastfeeding women — specialist advice is required before use.
  • People with severe renal impairment, including those on dialysis or with reduced GFR.
  • People with severe hepatic impairment or active liver disease.
  • Those with active haematological disease (blood disorders) or bone marrow concerns.
  • Known hypersensitivity to colchicine or any formulation ingredient.

Pre‑Prescription Screening Checklist

  • Renal function: recent eGFR or serum creatinine available.
  • Liver tests: current LFTs if there is known hepatic disease.
  • Current medicines: check for strong CYP3A4 or P‑gp inhibitors and other interacting drugs.
  • Pregnancy test for women of childbearing potential when clinically appropriate.

Absolute Contraindications

  • Hypersensitivity to colchicine.
  • Severe renal or hepatic impairment, especially with concurrent P‑gp or CYP3A4 inhibitors.
  • Avoid concomitant strong CYP3A4 or strong P‑gp inhibitors when renal or hepatic function is reduced.

Interaction With Activities

Common adverse effects from colchicine include dizziness, fatigue and gastrointestinal upset.

These symptoms can impair alertness, coordination and reaction times.

Patients should be advised not to drive, operate machinery or perform safety‑critical work if they feel dizzy, drowsy, nauseous or have blurred vision after taking colchicine.

Workers in safety‑critical roles should inform their employer about side effects that could affect performance and follow workplace policies.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Do not drive if you feel dizzy, drowsy, nauseous or have blurred vision after taking colchicine.

If you have no symptoms, follow usual fitness‑to‑drive rules and workplace policies.

Declare any side effects that affect alertness to your employer if you do safety‑critical work.

Usage Basics

INN, Brand Names Available In Australia

INN: colchicine.

Common international brand examples include Colcrys, Mitigare, Gloperba and Lodoco, with the 0.6 mg tablet being the most common strength in current packaging.

Local brand listings in Australia vary and should be confirmed via the TGA ARTG and pharmacy stock listings.

Form Strength Example Brands
Tablet 0.6 mg Colcrys, Lodoco (examples)
Capsule 0.6 mg Mitigare (example)
Oral Solution 0.6 mg/5 mL Gloperba (example)

Legal Classification (TGA‑Approved, PBS‑Listed)

Colchicine is classified as prescription‑only in regulated markets.

Check the TGA register for approval status of specific products and the PBS for subsidy eligibility and prescribing rules.

PBS listings influence cost to the patient and authority requirements for repeats.

  • Prescription required for supply.
  • Check repeats and authority requirements on the PBS if subsidy is claimed.
  • Keep accurate prescribing records and match the product to the prescription details before dispensing.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Acute gout flares:

  • Single 1.2 mg at onset then 0.6 mg one hour later (maximum 1.8 mg in 1 hour) as per common product labels.
  • Alternative regimens use 0.6 mg with dosing intervals guided by the product information and clinical judgement.

Prophylaxis:

  • 0.6 mg once or twice daily to prevent recurrent attacks.

Familial Mediterranean Fever (FMF):

  • Adults: 1.2–2.4 mg per day in one or two divided doses depending on response and tolerability.
  • Children ≥4 years: start 0.6–1.2 mg/day and titrate to effect as recommended.

Adjustments For Comorbidities

Reduce dose and monitor closely in elderly and frail patients due to increased toxicity risk.

In hepatic impairment, use reduced dosing and avoid in severe hepatic disease or active liver disease.

In moderate‑to‑severe renal impairment reduce dose or avoid; colchicine is contraindicated in dialysis/reduced GFR.

Avoid combination with strong CYP3A4 or P‑gp inhibitors where possible.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember unless the next scheduled dose is imminent.

Do not double up doses to make up for a missed tablet.

For acute single‑dose regimens follow the product label and seek pharmacist advice if uncertain.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

There are no major food interactions that prevent use of colchicine, but some dietary cautions apply.

  • Alcohol can exacerbate gout and add extra strain to the liver; advise moderation while on colchicine.
  • Large grapefruit intake may inhibit CYP3A4 and raise colchicine levels — recommend caution with grapefruit and grapefruit juice.
  • A normal Australian diet does not require routine restriction but counsel patients on alcohol moderation and hydration during gout flares.

Common Drug Conflicts

Some drug combinations increase colchicine concentrations and can cause severe, even fatal toxicity particularly when renal or hepatic function is impaired.

Interacting Drug Class / Example Clinical Effect Recommended Action
Strong CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole) Increased colchicine levels and toxicity risk Avoid co‑administration; if unavoidable reduce dose and monitor closely
Strong P‑gp inhibitors (e.g. ciclosporin, some antivirals) Reduced colchicine elimination, higher exposure Avoid or use with extreme caution and dose adjustment
Statins and certain fibrates Potential increased risk of myopathy when combined with colchicine Monitor for muscle pain and CK; assess renal function
Macrolide antibiotics May increase colchicine concentrations Avoid co‑administration where possible; choose alternative antibiotic

User Reports & Trends

What patients in Australia commonly say about colchicine.

Many patients report rapid onset of pain relief for acute gout when low doses are taken promptly.

Gastrointestinal side effects — especially diarrhoea and nausea — are the most common reasons people stop treatment.

Some patients use colchicine off‑label for inflammatory control under specialist care.

Access and price sensitivity affect adherence, particularly in rural and regional areas where PBS access and stock vary.

Sentiment Typical Feedback
Efficacy Often effective for acute gout at low doses; relief within hours reported by many
Tolerability GI upset common; fatigue and myalgia occasionally reported
Access Price and PBS status influence continuation; rural stock issues noted

Patient Tips From Australian Forums And Reviews

  • Store medication correctly and check expiry dates.
  • Report severe or persistent gastrointestinal symptoms to a pharmacist or GP.
  • Always show a current medication list to the pharmacist to check for interactions.

Clinicians and pharmacists should monitor local review sites, pharmacist consultation notes and report adverse events to the TGA to help identify regional trends.

Access & Purchase Options

National Chains

Colchicine is prescription‑only and major pharmacy chains dispense it with a valid prescription.

PBS scripts may reduce out‑of‑pocket cost depending on listing and patient entitlements.

Stock and brand may vary by site — it is sensible to call ahead in rural or remote areas.

  • Bring the prescription, concession card if applicable, and a current medication list when you visit the pharmacy.

Online Pharmacies And Telehealth E‑Prescriptions

E‑prescriptions issued via telehealth are accepted by many Australian pharmacies.

Verify pharmacy accreditation and PBS claims when ordering online.

Confirm brand, strength (0.6 mg tablets are common) and shipping conditions before purchase.

  • Check the pharmacy has TGA/AHPRA accreditation displayed and a working pharmacist contact number.
  • Use secure payment channels and confirm PBS concession or authority processing where relevant.
  • Review shipping times and privacy policies for discreet delivery.

In our online pharmacy, lengout is available without a prescription, with discreet delivery to Australia in 9-21 days.

Mechanism & Pharmacology

Simplified Explanation

Colchicine works by disrupting microtubule formation in neutrophils, which reduces their migration to inflamed tissues.

That action dampens the inflammatory response responsible for pain and swelling in gout flares and FMF attacks.

At low doses colchicine shows anti‑inflammatory effects that have been explored in cardiovascular trials.

Clinical Terms

ATC: M04AC01 — an antigout preparation without uric acid lowering effect.

Onset: symptom relief can begin within hours for acute attacks when appropriate dosing is used.

Accumulation and toxicity occur with interacting drugs or organ impairment that affects elimination.

  • Microtubules: cell structures important for neutrophil movement that colchicine disrupts.
  • P‑gp: P‑glycoprotein transporter involved in drug elimination; inhibitors raise colchicine levels.
  • CYP3A4: liver enzyme that metabolises colchicine; inhibitors increase exposure.
  • ATC Code: the anatomical therapeutic chemical classification for colchicine is M04AC01.

Indications & Off‑Label Uses

Approved Indications By TGA

Typical indications internationally include treatment of acute gout flares, gout prophylaxis and familial Mediterranean fever (FMF).

Local TGA product information and Consumer Medicine Information (CMI) should be checked for exact approved uses in Australia.

Low‑dose colchicine has also been studied for secondary cardiovascular prevention in trials associated with brands such as Lodoco.

Off‑Label Uses In Australian Practice

Off‑label applications may include pericarditis and certain inflammatory dermatological conditions when used under specialist supervision.

Always document informed consent and specialist guidance when using colchicine off‑label.

Indication Typical Dose Evidence Level / Australian Acceptance
Acute Gout 1.2 mg then 0.6 mg 1 hour later or 0.6 mg regimens Strong evidence for symptom relief; commonly used
FMF 1.2–2.4 mg/day in adults Established indication internationally
Pericarditis (off‑label) Low‑dose regimens under specialist care Some supporting evidence; specialist guided

Key Clinical Findings

What the evidence and guidelines say in brief.

  • Low‑dose colchicine reduces pain in acute gout when given promptly at recommended doses.
  • Colchicine prevents FMF attacks when used chronically at the lowest effective dose.
  • Low‑dose regimens showed benefit in selected cardiovascular trials, reducing recurrent events in some studies.
  • GI side effects are the main tolerability issue and often limit use.
  • Serious toxicity is linked to drug interactions and organ impairment affecting elimination.
Trial / Source Population Dose Outcome
Colchicine Trials (selected) Adults with acute gout or cardiovascular risk Low‑dose regimens (0.5–0.6 mg/day or acute dosing) Reduced pain in gout; some cardiovascular event reduction in specific trials

Clinicians should consult original peer‑reviewed trials, meta‑analyses and TGA/PBS guidance for full details before changing practice.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Drug Indication Onset PBS Status Contraindications
Colchicine Acute gout, prophylaxis, FMF Hours (acute dosing) Varies by product Severe renal/hepatic impairment, hypersensitivity
NSAIDs (indomethacin, naproxen) Acute gout pain control Hours PBS listed options available Peptic ulcer disease, severe renal impairment, heart failure
Allopurinol / Febuxostat Urate‑lowering long term Days to weeks (for urate lowering) PBS listed Severe hypersensitivity; monitor renal function
Anakinra Refractory inflammatory cases Variable Not routine PBS for gout Infection, specialist use only

Pros And Cons Checklist

  • Efficacy: colchicine effective for acute gout and FMF; NSAIDs effective for acute pain control.
  • Side Effects: colchicine — GI upset; NSAIDs — GI, renal, cardiovascular concerns.
  • Monitoring Needs: colchicine — renal and hepatic checks in at‑risk patients; urate‑lowering agents — urate and liver monitoring.
  • PBS Eligibility: check PBS listings and authority requirements for cost savings.

Common Questions

Pharmacy Consultation FAQs

  • How quickly will it work? — One to several hours for acute gout when dosed correctly.
  • Will it upset my stomach? — Yes, GI upset including diarrhoea and nausea is common; report severe diarrhoea.
  • Can I take it with my other meds? — Bring a full medicine list to the pharmacist; check for CYP3A4 and P‑gp inhibitors.
  • Is it safe in pregnancy? — Avoid unless advised by a specialist; specialist guidance required for pregnant or breastfeeding women.

When To Seek Urgent Care

  • Severe or persistent diarrhoea, vomiting or abdominal pain.
  • Muscle weakness, unexplained bruising or bleeding, or signs of infection.
  • Any signs of severe allergic reaction such as rash with breathing difficulty.

Document counselling and report suspected adverse events to the TGA.

Price & Access Comparison

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Supplier Typical OOP Price PBS Subsidy Status Prescription Required
Major Chemist Chain (in‑store) Varies — often cheaper with PBS concession Varies by brand and listing Yes
Independent Pharmacy Varies Varies Yes
Online Pharmacy Varies; check shipping costs Can process PBS e‑scripts Yes (e‑prescription accepted)

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Use PBS scripts and concession entitlements to reduce cost where eligible.
  • Ask about generic substitution where allowed to save money.
  • Call ahead to confirm stock in remote or rural pharmacies.

Always verify current PBS listings and concession status before advising patients on cost.

Registration & Regulation

TGA Approval

Colchicine is regulated as prescription‑only in Australia.

Check the TGA ARTG for current product registrations and updated product information before prescribing or dispensing.

PBS Subsidy Details

PBS subsidy status can change over time, and specific brands may have different listings or authority requirements.

  • Verify whether the colchicine product and patient are eligible for PBS subsidy.
  • Confirm whether an authority prescription is required for subsidised supply.
  • Report suspected adverse reactions to the TGA’s DAEN and consult the TGA website for regulatory updates.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store colchicine at 20–25°C, with permitted brief excursions between 15–30°C.

Keep tablets and solutions in their original packaging and protect them from moisture and direct sunlight.

In hot or humid Australian homes avoid storing medication in the bathroom or near heat sources.

Do not refrigerate or freeze tablets or oral solutions.

  • Keep out of reach of children.
  • Check expiry dates before use.
  • Use a cool, dry cabinet away from direct sunlight for storage.

Cold‑Chain Handling For Pharmacies

  • Oral solutions should not be frozen and must be stored per the manufacturer’s instructions.
  • Maintain temperature logs during storage and transport when required by product guidance.
  • Quarantine and assess product integrity after any temperature excursion.

Guidelines For Proper Use

Australian Pharmacist Counselling Points

Confirm the indication and dose, noting 0.6 mg strengths are common.

Explain common GI side effects and advise what to do if they occur.

Review all current medicines for CYP3A4 and P‑gp inhibitors and counsel on pregnancy and breastfeeding cautions.

Explain missed dose rules and advise on actions in suspected overdose — seek urgent medical care.

Discuss driving and workplace safety if side effects affect alertness.

  • Give written CMI and clear dosing instructions.
  • Document counselling in the patient record.
  • Arrange follow‑up testing for renal or hepatic function where indicated.

Patient Advice From PBS And National Health Authorities

  • Encourage patients to use the CMI and PBS resources for cost and repeat information.
  • Advise follow‑up with the GP for monitoring and to report adverse events to the TGA.
  • Provide a one‑page action plan for acute gout attacks including when to use colchicine and when to seek help.

Useful take‑home resources include the product CMI, the TGA website, the PBS lookup tool and direct pharmacist contact details for follow up.

Delivery Across Australia

City Region Delivery time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Geelong Victoria 9-14 days
Cairns Queensland 14-21 days
Townsville Queensland 14-21 days
Alice Springs Northern Territory 14-21 days

Related products